Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809214 | 0.93 | MCL1 (0.41) | MCL1KMT2APOLBGRIN2B | |
| SCHEMBL23809236 | 0.91 | GRIN2B (0.44) | MCL1PTGS2KMT2ANPC1RAB9A | |
| SCHEMBL26581555 | 0.87 | MCL1 (0.46) | MCL1PTGS2KMT2ADRD2HTR2A | |
| SCHEMBL20604762 | 0.87 | MCL1 (0.43) | MCL1PTGS2KMT2ADRD2HTR2A | |
| SCHEMBL23809237 | 0.83 | DRD2 (0.43) | MCL1DRD2HTR2AICMT | |
| SCHEMBL23809510 | 0.82 | GRIN2B (0.39) | MCL1GRIN2B | |
| SCHEMBL26581336 | 0.81 | GRIN2B (0.50) | MCL1POLBGRIN2B | |
| SCHEMBL20604943 | 0.80 | GRIN2B (0.43) | MCL1KMT2AGRIN2B | |
| SCHEMBL20604849 | 0.79 | PTGS2 (0.48) | PTGS2DRD2NPC1RAB9AGRIN2B | |
| SCHEMBL26581333 | 0.78 | GRIN2B (0.52) | MCL1PTGS2KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | MCL1 1/4885PTGS2 2060/4885KMT2A 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.